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Background: This study compared efficacy and safety of the selective relaxant binding agent sugammadex (2 mg/kg)
with neostigmine (50 μg/kg) for neuromuscular blockade (NMB) reversal in Chinese and Caucasian subjects.
Methods: This was a randomized, active-controlled, multicenter, safety-assessor-blinded study (NCT00825812) in
American Society of Anesthesiologists Class 1-3 subjects undergoing surgery with propofol anesthesia. Rocuronium
0.6 mg/kg was administered for endotracheal intubation, with 0.1–0.2 mg/kg maintenance doses given as required.
NMB was monitored using TOF-Watch® SX. At second twitch reappearance, after last rocuronium dose, subjects
received sugammadex 2 mg/kg or neostigmine 50 μg/kg plus atropine 10–20 μg/kg, according to randomization.
Primary efficacy variable was time from sugammadex/neostigmine to recovery of the train-of-four (TOF) ratio to 0.9.
Results: Overall, 230 Chinese subjects (sugammadex, n = 119, neostigmine, n = 111); and 59 Caucasian subjects
(sugammadex, n = 29, neostigmine, n = 30) had evaluable data. Geometric mean (95% CI) time to recovery to TOF
ratio 0.9 was 1.6 (1.5–1.7) min with sugammadex vs 9.1 (8.0–10.3) min with neostigmine in Chinese subjects.
Corresponding times for Caucasian subjects were 1.4 (1.3–1.5) min and 6.7 (5.5–8.0) min, respectively. Sugammadex
2 mg/kg was generally well tolerated, with no serious adverse events reported. There was no residual NMB or
recurrence of NMB.
Conclusion: Both Chinese and Caucasian subjects recovered from NMB significantly faster after sugammadex
2 mg/kg vs neostigmine 50 μg/kg, with a ~5.7 times (p < 0.0001) faster recovery with sugammadex vs neostigmine
in Chinese subjects. Sugammadex was generally well tolerated.
Trial registration: ClinicalTrials.gov Identifier: NCT00825812.
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Neuromuscular blockade (NMB) is often used during
surgery to facilitate tracheal intubation and to improve
surgical conditions. Acetylcholinesterase inhibitors such
as neostigmine are commonly administered to reverse
NMB at the end of surgery and to reduce the risk of re-
sidual paralysis and associated adverse respiratory events
[1,2]. However, these agents may provide slow and un-
predictable recovery [3], and are associated with several* Correspondence: xmwu2784@hotmail.com
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unless otherwise stated.unwanted side-effects, both alone and in combination
with anticholinergic agents [4,5].
The selective relaxant-binding agent sugammadex
(Bridion®, MSD, Oss, The Netherlands) has been shown to
rapidly and completely reverse the effects of the NMB
agents rocuronium [3,6] and vecuronium [7]. Further-
more, sugammadex is equally effective for reversal of
rocuronium-induced NMB under both propofol and
sevoflurane maintenance anesthesia [6]. Sugammadex is
marketed for reversal of rocuronium- and vecuronium-
induced NMB in over 40 countries worldwide.
Data on the efficacy and safety of sugammadex in
Chinese subjects are required. The primary objective of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of sugammadex 2 mg/kg compared with neostigmine
50 μg/kg plus atropine 10–20 μg/kg for reversal of moder-
ate rocuronium-induced NMB in Chinese and Caucasian
subjects. Key secondary objectives were to show faster re-
covery from rocuronium-induced NMB with sugammadex
vs neostigmine in Caucasian subjects and to demon-
strate equivalence in recovery times between Chinese and
Caucasian subjects.
Methods
Study subjects and study design
This was a randomized, parallel-group, multicenter, safety-
assessor-blinded study (www.clinicaltrials.gov; NCT00825812;
protocol P05768), conducted from February to September,
2010. The study was conducted at six sites in China and
four sites in Europe (two sites in Denmark and one site
each in Belgium and Norway). The study was conducted
in accordance with principles of Good Clinical Practice
and was approved by the appropriate Institutional Review
Board (IRB)/Independent Ethics Committee at each
study site. For the University Hospitals Leuven, IRB ap-
proval was provided by UZ Gasthuisberg Central IRB/EC,
Leuven, Belgium. For the Vejle Hospital, IRB approval was
provided by The Ethical Committee of Science for the
Syddanmark Region, Vejle, Denmark. For the Asker and
Baerum Hospital, IRB approval was provided by the
Regional Committee for Medical Research Ethics for
South-East Norway (B), Oslo, Norway. For the Peking Union
Medical College Hospital, IRB approval was provided by
the Peking Union Medical College Hospital IRB/EC, Beijing,
China. For the Beijing Chaoyang Hospital, IRB approval
was provided by Beijing Chaoyang Hospital IRB/EC,
Beijing, China. For the Peking University First Hospital,
IRB approval was provided by Peking University First
Hospital IRB/EC, Beijing, China. For the West China
Hospital, IRB approval was provided by West China Hospital
IRB/EC, Sichuan, China. For the Xijing Hospital, IRB
approval was provided by Xijing Hospital affiliated to
Fourth Military Medical University IRB/EC, Xi’an, China.
For the Union Hospital, IRB approval was provided
by Union Hospital Tongj Medical College Huazhong
University of Science IRB/EC, Hibei Province, China. For
the Hillerød Hospital, IRB approval was provided by The
Ethical Committee of Science for the Syddanmark region,
Vejle, Denmark. All subjects were required to provide writ-
ten, informed consent.
This study involved Chinese and Caucasian subjects
undergoing elective surgery with propofol anesthesia,
using NMB with rocuronium. For inclusion, subjects had
to be 18–64 years of age and of American Society of Anes-
thesiologists Class 1–3. Chinese subjects had to be born in
China, have never emigrated out of China and have a
Chinese home address. Similarly, Caucasian subjects hadto be born in Europe have never emigrated out of Europe
and have a European home address.
Subjects were excluded from the study if they had ana-
tomical malformations expected to lead to difficult tra-
cheal intubation, neuromuscular disorders affecting NMB,
significant renal/hepatic dysfunction (as determined by
the investigator), (family) history of malignant hyperther-
mia, allergy to general anesthesia medications, contraindi-
cation to study drugs or a clinically significant condition
that may interfere with the trial (as determined by the
investigator).
Screening took place ≤ 7 days before study treatment
administration. Eligible subjects were randomized via a
central randomization system. The sponsor produced a
computer-generated randomization schedule with treat-
ment codes in blocks, using a validated SAS-based appli-
cation. The schedule associated each treatment code with
a subject number, and subjects were randomized in a 1:1
ratio to receive either sugammadex 2 mg/kg or neostig-
mine 50 μg/kg with atropine 10–20 μg/kg.
Study procedures
An intravenous (IV) cannula was inserted for the admin-
istration of anesthetic drugs. Anesthesia was induced
and maintained with IV propofol according to the clin-
ical needs of the subject. Opioids could be administered
according to local practice. Other anesthetic practices,
e.g. use of methods such as bispectral index or entropy
monitoring for measuring depth of anesthesia, were per-
formed according to routine practices at the study site.
Propofol was administered until a train-of-four (TOF) ra-
tio of 0.9 has been established by the TOF-Watch® SX
(Organon Ireland Ltd., a subsidiary of Merck and Co.,
Swords, Co. Dublin, Ireland).
After induction of anesthesia but before rocuronium
administration, neuromuscular monitoring was carried
out using continuous acceleromyography at the adductor
pollicis muscle using the TOF-Watch® SX, in agreement
with guidelines for Good Clinical Research Practice in
pharmacodynamic studies of neuromuscular blocking
agents [8,9]. Following induction of anesthesia, the TOF-
Watch® SX was calibrated with the built-in calibration
modus (CAL 2) after 5-sec 50 Hz tetanic stimulation pre-
ceded by a repetitive TOF stimulation for 1 min. After
calibration, a 3–4-min repetitive TOF stimulation was re-
quired before administration of rocuronium to ensure a
stable response. TOF stimulation was applied every 15 sec
at the ulnar nerve until the end of anesthesia or at least
until recovery of the TOF ratio to 0.9. Neuromuscular data
were collected via an interface to a computer by means of
the TOF-Watch® SX Monitoring Program, version 2.3.
After the TOF-Watch® SX had been set up, rocuronium
0.6 mg/kg was administered within 10 sec as a fast-running
IV infusion. Tracheal intubation was then performed.
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given as required throughout anesthesia. After the last
dose of rocuronium, at reappearance of second twitch, a
single IV dose of sugammadex 2 mg/kg or a single IV dose
of neostigmine 50 μg/kg plus atropine 10–20 μg/kg was
administered to reverse NMB. All doses of neuromuscular
blocking agents and reversal agents were administered
based on actual body weight.
Efficacy analyses
The primary efficacy variable was the time from the start
of administration of sugammadex or neostigmine/atropine
to recovery of the TOF ratio to 0.9. Secondary efficacy var-
iables included time to recovery of the TOF ratio to 0.7
and 0.8.
In line with mean data from other studies within the
sugammadex clinical trial programme, time to recovery of
the TOF ratio to 0.9 > 6 min for a subject receiving sugam-
madex 2 mg/kg was classed as a prolonged recovery time.
Safety
Safety assessments were performed by a safety assessor
who was blinded to the treatment administered, and in-
cluded monitoring of adverse events (AEs), vital signs
and physical examination. Treatment-related AEs were
those AEs considered by the investigator to be related to
the study treatment (sugammadex or neostigmine). Risk
factors for post-operative nausea and vomiting (PONV)
[10] were assessed at baseline, and the relationship be-
tween the number of risk factors and occurrence of PONV
during the study was evaluated. Additionally, subjects were
assessed for evidence of residual NMB or recurrence of
NMB, using both the TOF-Watch® SX and clinical signs.
In addition to safety assessments during screening and
the peri-operative period, further assessments were made
at a post-anesthetic visit (10 h after study drug administra-
tion, or the day following the operation) and at the follow-
up assessment on Day 8.
Statistical analysis
For regulatory considerations of a new pharmaceutical
compound in China, 100 evaluable subjects per treatment
group are required. For the primary objective, assuming a
maximum drop-out rate of 13%, 115 evaluable subjects
were to be enrolled per treatment group across the Chinese
sites. It was estimated that this would give a power of at
least 95% to demonstrate that recovery of the TOF ratio
to 0.9 after sugammadex 2 mg/kg is at least two times fas-
ter than after neostigmine 50 μg/kg, testing at a signifi-
cance level of 5% (two-sided), and assuming that the
coefficient of variation (CV) in both groups is < 2.2 (based
on previous sugammadex studies). For the secondary
objectives, enrollment of 30 Caucasian subjects per treat-
ment group was required to ensure a power of 80% todemonstrate equivalence in recovery times between Chinese
and Caucasian subjects (assuming a standard deviation
of 1.5 min), and a power of 95% to demonstrate at least
three times faster recovery with sugammadex 2 mg/kg
vs neostigmine 50 μg/kg in Caucasian subjects (with a
CV of 1.1).
The primary analysis was performed on the full analysis
set (equivalent to an intent-to-treat (ITT) population,
which included all subjects who received the randomized
study drug and had at least one efficacy assessment. In the
event of missing data, values were imputed, using a worst-
case scenario for sugammadex [7].
For the primary analysis, logarithms of the times from
start of sugammadex and neostigmine administration to
recovery of the TOF ratio to 0.9 in the Chinese subjects
were compared using analysis of variance on log recov-
ery times adjusted for study site effects. Recovery times
are now known to follow an approximately lognormal
distribution and thus recovery times were summarized
by geometric means and associated 95% confidence
Intervals (CIs).
Data for the secondary objective of demonstrating fas-
ter recovery in Caucasian subjects after sugammadex vs
neostigmine were analyzed as for the primary objective.
For the secondary objective of demonstrating equiva-
lence in recovery times of the TOF ratio to 0.9 between
Chinese and Caucasian subjects, analyses were performed
using a non-parametric CI approach, which enables a quan-
titative measure of any differences between the groups.
The estimated median difference between the two subject
groups and the corresponding two-sided 97.5% CI were
calculated using the Hodges–Lehmann estimator for treat-
ment effect and Moses for CI of estimated treatment effect.
Equivalence in efficacy between Chinese and Caucasian
subjects was considered to be demonstrated when the
97.5% CI for the median difference between the groups
was within a -1 to +1 min interval.
Safety analyses were performed for the all-subjects-
treated (AST) group, and included all randomized sub-
jects who received a dose of study medication.
Results
Patient disposition and flow (according to CONSORT guide-
lines) is shown in Figure 1. Of 247 randomized Chinese
subjects, 16 subjects discontinued the study, and one sub-
ject who completed the study had missing efficacy data.
Hence, 231 Chinese subjects received study treatment and
were included in the safety analysis (AST group) and 230
Chinese subjects with evaluable data were included in the
efficacy analysis (full analysis set; sugammadex, n = 119,
neostigmine, n = 111). In total, 61 Caucasian subjects were
randomized, of whom 60 received treatment (AST group),
and 59 had evaluable data (full analysis set; sugammadex,
n = 29, neostigmine, n = 30) (Figure 1).
Figure 1 Patient disposition and flow through the study (in accordance with CONSORT guidelines). FAS: full analysis set.
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groups between subjects receiving sugammadex and those
receiving neostigmine (Table 1). Anesthesia was induced
and maintained with propofol in all Chinese and Caucasian
subjects. The most frequently administered opioid was
remifentanil (Table 1).
Efficacy analyses
In the Chinese subjects, geometric mean (95% CI) time to
recovery of the TOF ratio to 0.9 was 1.6 (1.5–1.7) min
with sugammadex vs 9.1 (8.0–10.3) min with neostigmine
(Figure 2). In total, 91% of Chinese subjects recovered to a
TOF ratio of 0.9 within 3 min after administration of
sugammadex, whereas only 1.8% recovered within 3 min
after neostigmine. Fastest and slowest times to recovery
following neostigmine were 2.7 and 60.4 min, respectively.
Figure 3 shows the cumulative percentage of Chinese and
Caucasian subjects recovering to a TOF ratio of 0.9 over
time. Recovery time was estimated to be 5.7 times faster
with sugammadex vs neostigmine in the Chinese subjects
(95% CI 4.9–6.6; p < 0.0001).
An outlying recovery time of 6.2 min was observed for
one Chinese subject after receiving sugammadex. For
this subject, TOF 0.7 and 0.8 were reached at 0.9 min and
1.4 min after sugammadex, respectively, and were thuswithin normal ranges. However, due to technical issues
with neuromuscular monitoring, an unusually high first
twitch value affected the TOF ratio and caused the delay
in reaching TOF 0.9.
In the Caucasian subjects, geometric mean (95% CI)
time to recovery of the TOF ratio to 0.9 was 1.4 (1.3–1.5)
min and 6.7 (5.5–8.0) min for those receiving sugamma-
dex and neostigmine, respectively (Figure 2). All Cauca-
sian subjects recovered to a TOF ratio of 0.9 within 2 min
from start of administration of sugammadex, while none
recovered within 2 min after receiving neostigmine. Fast-
est and slowest times to recovery following neostigmine
were 3.0 and 31.4 min, respectively. In Caucasian subjects
there was an estimated 4.8 times faster recovery with
sugammadex vs neostigmine (95% CI 3.7–6.0; p < 0.0001).
Comparable geometric mean times to recovery to TOF
0.9 following treatment with sugammadex were observed
in Chinese and Caucasian subjects (1.6 and 1.4 min, re-
spectively; Table 2). The estimated median difference was
7 sec (97.5% CI -5, 21 sec). The 97.5% CI was within the
pre-specified range of -1 to +1 min, supporting equiva-
lence of efficacy between Chinese and Caucasian subjects.
Following neostigmine treatment, recovery was 1.37 (95%
CI: 1.05–1.78) times faster in Caucasian vs Chinese sub-
jects (6.7 vs 9.1 min, respectively).
Table 1 Baseline characteristics and anesthetic agents received (all-subjects-treated group)
Chinese Caucasian
Sugammadex (n = 120) Neostigmine (n = 111) Sugammadex (n = 29) Neostigmine (n = 31)
Gender (n, %)
Female 78 (65) 86 (77) 25 (86) 28 (90)
Male 42 (35) 25 (23) 4 (14) 3 (10)
Race (n, %)
White 0 (0) 0 (0) 29 (100) 31 (100)
Asian 120 (100) 111 (100) 0 (0) 0 (0)
Age (Mean, SD years) 39.9 (10.8) 39.4 (10.8) 52.0 (10.3) 51.9 (7.3)
Weight (Mean, SD kg) 62.8 (12.6) 61.3 (11.3) 72.8 (10.8) 72.7 (11.8)
Height (Mean, SD cm) 163.8 (7.7) 163.7 (6.7) 169.1 (6.6) 167.9 (6.8)
BMI (mean, SD kg/m2) 23.3 (3.6) 22.8 (3.3) 25.5 (3.5) 25.9 (4.3)
ASA class (n, %)
1 90 (75) 82 (74) 12 (41) 16 (52)
2 28 (23) 29 (26) 15 (52) 15 (48)
3 2 (2) 0 (0) 2 (7) 0 (0)
Anesthetic agents received (n, %)
Propofol 120 (100) 111 (100) 29 (100) 31 (100)
Remifentanil 101 (84) 92 (83) 20 (69) 23 (74)
Fentanyl 65 (54) 66 (59) 7 (24) 10 (32)
Sufentanyl 41 (34) 38 (34) 9 (31) 8 (26)
Tramadol 2 (2) 3 (3) 0 (0) 0 (0)
Butorphanol 0 (0) 1 (1) 0 (0) 0 (0)
ASA: American Society of Anesthesiologists; BMI: Body mass index; SD: Standard deviation.
Figure 2 Time from start of administration of sugammadex or
neostigmine to recovery of the train-of-four (TOF) ratio to 0.9
in Chinese and Caucasian subjects (full analysis set).
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were also observed for TOF ratios of 0.7 and 0.8 in both
Chinese and Caucasian subjects (Table 2). For time to
recovery to TOF 0.7, estimated median difference (95% CI)
between Chinese and Caucasian subjects was 5 sec
(-2, 13 sec) and for time to recovery to TOF 0.8 it was
7 sec (-1, 14 sec).Figure 3 Cumulative percentage of Chinese and Caucasian
subjects recovering to a train-of-four (TOF) ratio of 0.9 over
time (full analysis set).
Table 2 Comparison of time (min) from administration of sugammadex vs neostigmine to recovery of the train-of-four
(TOF) ratio to 0.7, 0.8 and 0.9 in Chinese and Caucasian subjects (full analysis set, with imputed data)
Chinese Caucasian
Sugammadex (n = 119) Neostigmine (n = 111) Sugammadex (n = 29) Neostigmine (n = 30)
TOF 0.7
Geometric mean (95% CI) 1.1 (1.1–1.2) 4.4 (4.0–4.9) 1.0 (0.9–1.1) 3.4 (3.0–3.8)
Range 0.4–2.1 1.7–32.4 0.6–1.7 1.9–7.9
TOF 0.8
Geometric mean (95% CI) 1.3 (1.2–1.4) 6.0 (5.4–6.7) 1.2 (1.1–1.3) 4.6 (4.0–5.4)
Range 0.6–2.8 2.2–-59.6 0.8–1.7 2.4–14.1
TOF 0.9*
Geometric mean (95% CI) 1.6 (1.5–1.7) 9.1 (8.0–10.3) 1.4 (1.3-1.5) 6.7 (5.5-8.0)
Range 0.6–6.2 2.7–60.4 0.8–2.0 3.0–31.4
CI: Confidence intervals.
*Two Chinese subjects (one sugammadex, one neostigmine) had missing times to recovery of the TOF ratio to 0.9. In addition, the Central Independent
Adjudication Committee considered the time to recovery of the TOF ratio to 0.9 to be unknown in another six Chinese subjects (three sugammadex, three
neostigmine). Values were therefore imputed for these eight subjects.
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ment group was observed for the Chinese or European
centers (p = 0.77 and p = 0.14, respectively). Similarly, no
significant study site effect was observed (corresponding
p values: p = 0.11 and p = 0.42).Table 3 Adverse events (AEs) occurring for ≥ 5% subjects in a
(all-subjects-treated group)
Chinese
Sugammadex (n = 120) Neostig
Subjects with any AE (n, %) 84 (70) 91 (82)
Abdominal pain 1 (1) 6 (5)
Upper abdominal pain 6 (5) 2 (2)
Nausea 10 (8) 13 (12)
Odynophagia 6 (5) 3 (3)
Vomiting 11 (9) 11 (10)
Fatigue – –
Pyrexia 16 (13) 16 (14)
Sensation of foreign body 7 (6) 4 (4)
Cardiac anesthetic complication 1 (1) 6 (5)
Incision site pain 28 (23) 26 (23)
Procedural hypotension – –
Procedural nausea 4 (3) 7 (6)
Procedural pain 10 (8) 10 (9)
Procedural vomiting 4 (3) 7 (6)
Wound complication 3 (3) 2 (2)
Dizziness 11 (9) 21 (19)
Headache 5 (4) 6 (5)
Insomnia 2 (2) 1 (1)
Vaginal hemorrhage 5 (4) 9 (8)
Increased upper airway secretion 5 (4) 10 (9)Safety
The most frequently reported AEs, regardless of relation
to the study drug, were incision site pain, procedural
pain, pyrexia, nausea and dizziness (Table 3). The per-
centage of subjects who experienced at least one post-ny treatment group, regardless of relation to study drug
Caucasian
mine (n = 111) Sugammadex (n = 29) Neostigmine (n = 31)
20 (69) 26 (84)
1 (3) 1 (3)
– 2 (6)










13 (45) 12 (39)
– –
3 (10) 3 (10)
2 (7) –
1 (3) 1 (3)
2 (7) 2 (6)
– –
– –
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dex vs neostigmine, and was similar between Chinese and
Caucasian subjects: 70% and 69%, respectively, following
sugammadex, and 82% and 84%, respectively, following
neostigmine.
AEs considered by the investigator to be possibly or
probably treatment-related were reported for 9% and
3% of sugammadex-treated Chinese and Caucasian sub-
jects, respectively, and for 18% and 35% of corresponding
neostigmine-treated subjects. The most frequently re-
ported treatment-related AE was anesthetic cardiac com-
plication (in 11 subjects in total [1% and 0% of Chinese
and Caucasian subjects after sugammadex and 5% and
13% of Chinese and Caucasian subjects after neostigmine,
respectively]). All subjects with anesthetic cardiac compli-
cation were reported to have bradycardia or decreased
heart rate. Other frequently reported treatment-related
AEs were procedural hypotension (in five subjects in total
[16% Caucasian subjects receiving neostigmine and no
sugammadex-treated subjects]), and increased upper air-
way secretion (in six subjects in total [2% Chinese subjects
receiving sugammadex and 4% Chinese subjects receiv-
ing neostigmine, and not reported in Caucasian sub-
jects]). All AEs related to bradycardia or low heart rate
were considered by the investigator to be possibly or prob-
ably treatment-related; this included all subjects with
anesthetic cardiac complication as noted above, four sub-
jects with procedural complication (three Chinese, one
Caucasian, all in the neostigmine group), and one Chinese
subject in the sugammadex group who had mild bradyar-
rhythmia. In total, two Chinese subjects (2%) and no Cauca-
sian subjects in the sugammadex group and nine Chinese
subjects (8%) and five Caucasian (16%) subjects in the
neostigmine group had at least one bradycardia or low
heart rate event.
Serious AEs were reported for three subjects, all fol-
lowing treatment with neostigmine, and all were consid-
ered unlikely to be related to the study drug by the
investigator. One Chinese subject experienced incision
site hemorrhage of severe intensity. Enterococcal
bacteremia and anastomotic leak of moderate and severe
intensity, respectively, were experienced by two Cauca-
sian subjects.
Three subjects (one Chinese and two Caucasian) who re-
ceived sugammadex and three subjects (all Chinese) who
received neostigmine had AEs which were considered by
the study sponsor to be potentially related to muscle weak-
ness. Two of these AEs were considered by the investigator
to be potentially treatment-related (mild hypoventilation in
a Chinese subject who received sugammadex and severe
muscular weakness in a Chinese subject who received neo-
stigmine). Four of these AEs were considered unlikely to
be treatment-related. The mild hypoventilation was treated
with supplemental oxygen and resolved the next day; thesubject had received three maintenance doses of rocuro-
nium and a single IV dose of tramadol 100 mg at 3 min
before sugammadex administration. The severe muscular
weakness (weakness of lower limbs) began 7 h after neo-
stigmine administration and resolved the next day; the
subject experiencing this AE received no maintenance
rocuronium dose and received a prescribed dose of genta-
micin 80 000 U at 6 h after neostigmine administration.
There was no evidence of residual NMB or recurrence of
NMB, either clinically or based on neuromuscular moni-
toring for any patient.
Ten Chinese subjects (seven receiving sugammadex
and three receiving neostigmine) had AEs considered by
the study sponsor to be potentially attributable to drug
hypersensitivity (e.g. mild-to-moderate rash, pruritis, fa-
cial swelling, facial flushing). All except one of these AEs
(moderate rash on chest following sugammadex) were
considered by the investigator to be unlikely to be related
to the study drug. This subject, who experienced moder-
ate rash on the chest, was treated with diphenhydramine
and recovered on the same day. There were no reports
consistent with anaphylaxis.
Events considered by the investigator to be likely re-
flective of bleeding were reported for eight (7%) Chinese
subjects treated with sugammadex (five cases of vaginal
hemorrhage, plus a case each of incision site hemorrhage,
uterine hemorrhage and occult blood stool), and for 12
(11%) Chinese subjects treated with neostigmine (nine
cases of vaginal hemorrhage, one case of incision site
hemorrhage, and two cases of melaena). One (2%) Cauca-
sian subject had a bleeding event; this patient experienced
post-procedural hematoma after lumpectomy surgery, and
was treated with neostigmine. None of these events were
considered by the investigator to be related to study
medication.
In total, PONV events were reported for 16 Chinese
(13%) and four Caucasian (14%) subjects who were treated
with sugammadex and 19 Chinese (17%) and seven Cau-
casian (23%) subjects who were treated with neostigmine.
Each subject had at least one PONV risk factor with the
majority of subjects having three risk factors.
Discussion
This was the first study comparing efficacy and safety
of sugammadex 2 mg/kg vs neostigmine 50 μg/kg
plus atropine 10–20 μg/kg for reversal of moderate
rocuronium-induced NMB in Chinese and Caucasian
subjects. Neostigmine was chosen as the comparator re-
versal agent as it is commonly used for NMB reversal in
many countries. Atropine was chosen as the anticholiner-
gic agent to reflect current clinical practice in China.
The main study finding was that recovery to a TOF
ratio of 0.9 was significantly faster after administration
of sugammadex 2 mg/kg compared with neostigmine
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Geometric mean time to a TOF ratio of 0.9 in Caucasian
subjects was 1.4 min and 6.7 min for sugammadex and
neostigmine, respectively, confirming the efficacy of sugam-
madex 2 mg/kg for reversal of moderate rocuronium NMB
in Caucasian subjects as demonstrated in previous studies
[3,11,12]. Furthermore, equivalence of efficacy of sugamma-
dex (i.e. time to recovery of the TOF ratio to 0.9) was dem-
onstrated between Chinese and Caucasian subjects.
The overall safety profile of sugammadex was shown to
be favorable, and no serious AEs reported in sugammadex-
treated subjects. The most frequently reported AEs were
incision site pain, procedural pain and nausea. Importantly,
there was no evidence of recurrence of NMB in any
patient, either clinically or according to neuromuscu-
lar monitoring.
A higher number of subjects in the neostigmine group
had at least one bradycardia or low heart rate event
compared with those in the sugammadex group. Brady-
cardia is a side-effect associated with the use of acetyl-
cholinesterase inhibitors such as neostigmine, although
co-administration with an anticholinergic agent would be
expected to counteract this [4]. It should be noted that, in
the current study, neostigmine 50 μg/kg was given to-
gether with 10–20 μg/kg atropine in a ratio ranging from
2.5:1 to 5:1, depending on local practice.
A total of seven Chinese subjects who received sugam-
madex and three who received neostigmine had AEs
consistent with drug hypersensitivity reactions, although
only one of these was considered by the investigator to
be possibly treatment-related (moderate rash on chest fol-
lowing sugammadex). None of the drug hypersensitivity
reports were consistent with anaphylaxis, and there were
no reports of drug hypersensitivity in Caucasian subjects.
Low incidences of suspected sugammadex-induced hyper-
sensitivity reactions have been reported in healthy volun-
teers [13,14]; Merck (Study P07042), data on file, and
as post-marketing events in case-reports [15-17]. Re-
ported reactions have varied from isolated skin reactions
to serious systemic reactions (i.e. anaphylaxis, anaphyl-
actic shock) and have occurred in patients with no
prior exposure to sugammadex [18]. There have also
been case reports of allergic drug reactions [19] and
anaphylaxis [20] following neostigmine, although these
reports are rare.
Overall, there were a total of 20 (9%) Chinese subjects
and one (2%) Caucasian subject for whom, at least one
event of bleeding was reported. The incidence of bleed-
ing was higher in Chinese patients, regardless of treat-
ment group, occurring in eight (7%) Chinese patients
receiving sugammadex and 12 (11%) receiving neostig-
mine. Underlying reasons for this are not clear, although
may be reflective of differences in surgical procedures.
None of the events were considered treatment-related.Of note, while previous Phase I studies demonstrated a
prolongation of activated partial thromboplastin time and
prothrombin time (international normalized ratio) in healthy
volunteers following sugammadex treatment [21,22], these
effects were not clinically relevant, and sugammadex has
since been shown not to be associated with an increased
risk of bleeding vs usual care [23].
There also appeared to be some general differences be-
tween the populations in the safety findings, with 23% of
Chinese subjects in both study groups reporting incision
site pain but with no reports of this AE for the Caucasian
subjects. Such differences may be reflective of the different
surgical procedures undergone by the Chinese vs Cauca-
sian subjects. Additionally, while the MedDRA system of
coding was used to ensure consistency wherever possible,
variations in local practices also may have contributed to
observed differences in the incidence of AEs.
As ethnicity and geographic location may affect the ef-
fectiveness and duration of action of drugs, it is import-
ant to investigate sugammadex in a variety of patient
populations. Differences in drug action between Chinese
and Caucasian/white subjects have been previously re-
ported for several drugs, [24-26] with at least some of
these differences likely to be due to differences in drug
metabolism, e.g. resulting from variations in cytochrome
P450 enzymes [27,28]. Inter-ethnic differences in drug
pharmacokinetics may also reflect differences in lipid
stores and body stature [29]. Importantly, the results of
the present study have excluded any clinically relevant
differences in the effectiveness of sugammadex 2 mg/kg
in Chinese compared with Caucasian subjects. However,
geometric mean times to recovery to TOF 0.9 following
neostigmine administration were 1.37 (95% CI 1.05–1.78)
times longer in Chinese vs Caucasian subjects. This result
is statistically significant; however, it is unclear why this
difference occurred. While there is no known race effect
for neostigmine, Chinese subjects have previously been
shown to be more sensitive to effects of atropine vs Cau-
casian subjects [26], and this may have potentially played
a role. Furthermore, spontaneous recovery from rocuro-
nium has previously been shown to be somewhat slower
in Chinese vs Caucasian patients [30], with the authors
concluding that reasons for the observed interethnic dif-
ference were likely to be multifactorial.
In the current study, Chinese and Caucasian subjects
treated with sugammadex had fewer anesthetic cardiac
complications than those treated with neostigmine. All AEs
termed “anesthetic cardiac complication” were incidences
of bradycardia or low heart rate, a well-recognized potential
side-effect of neostigmine [31].
In addition to the present study where sugammadex
was administered at moderate blockade, a recent study
demonstrated the efficacy and safety of sugammadex
4 mg/kg when administered at 1–2 post-tetanic counts
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support to the results of the current study.
Conclusions
In Chinese subjects, sugammadex 2 mg/kg provided sig-
nificantly more rapid reversal of moderate rocuronium-
induced NMB compared with neostigmine (p < 0.0001).
Efficacy of sugammadex 2 mg/kg was confirmed in Cauca-
sian subjects, and equivalence of efficacy was demonstrated
between Chinese and Caucasian subjects. Sugammadex
2 mg/kg was generally well-tolerated in both Chinese and
Caucasian subjects.
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